- Home
- PETZ vs IOBT Comparison
PETZ vs IOBT Comparison
Compare PETZ & IOBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$1.16
HOLD
Current Price
$0.04
Company Overview
Basic Information| Metric | PETZ | IOBT |
|---|---|---|
| Founded | 2002 | 2014 |
| Country | China | Denmark |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.6M | 12.7M |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PETZ | IOBT |
|---|---|---|
| Price | $1.16 | $0.04 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.25 |
| AVG Volume (30 Days) | 3.5K | ★ 20.9M |
| Earning Date | 04-24-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.77 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.89 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.68 | $0.03 |
| 52 Week High | $1.68 | $2.79 |
Technical Indicators
Market Signals| Indicator | PETZ | IOBT |
|---|---|---|
| Relative Strength Index (RSI) | 38.96 | 25.94 |
| Support Level | $0.96 | N/A |
| Resistance Level | $1.09 | $0.22 |
| Average True Range (ATR) | 0.04 | 0.02 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 0.00 | 15.92 |
Price Performance
Historical Comparison PETZ
IOBT
About PETZ TDH Holdings Inc.
TDH Holdings Inc is engaged in the business of manufacturing and selling pet food and restaurant operations. The company has two operating segments, which include Petfood sales and the Restaurant business. It has a focus on the Restaurant business segment and generates the majority of its revenue.
About IOBT IO Biotech Inc.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.